A Safety, Tolerability, and Pharmacokinetics Study of MK-... | NCT03565068 | Trialant
NCT03565068
Sponsor
Merck Sharp & Dohme LLC
Status
Completed
Last Update Posted
Mar 29, 2021Actual
Enrollment
75Actual
Phase
Phase 1
Conditions
Schizophrenia
Interventions
MK-8189
Placebo
Background AAP Therapy
Countries
United States
Protocol Section
Identification Module
NCT ID
NCT03565068
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
8189-007
Secondary IDs
ID
Type
Description
Link
MK-8189-007
Other Identifier
Merck
Brief Title
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
Official Title
A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.
Acronym
MDCS
Organization
Merck Sharp & Dohme LLCINDUSTRY
Status Module
Record Verification Date
Mar 2021
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Jun 20, 2018Actual
Primary Completion Date
Apr 3, 2020Actual
Completion Date
Apr 3, 2020Actual
First Submitted Date
Jun 1, 2018
First Submission Date that Met QC Criteria
Jun 20, 2018
First Posted Date
Jun 21, 2018Actual
Results Waived
Not provided
Results First Submitted Date
Mar 2, 2021
Results First Submitted that Met QC Criteria
Mar 2, 2021
Results First Posted Date
Mar 29, 2021Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Mar 2, 2021
Last Update Posted Date
Mar 29, 2021Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Merck Sharp & Dohme LLCINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This 4-panel study will evaluate the safety, tolerability, pharmacokinetics (PK) and corrected QT interval (QTc) effect of MK-8189 versus placebo, as monotherapy in healthy participants (Panel A) including those of Japanese descent, as monotherapy in participants with schizophrenia (Panel B), as add-on therapy in participants with schizophrenia (Panel C), and under an alternative dosing regimen as monotherapy in participants with schizophrenia (Panel D). Analysis of QTc effect will be exploratory. There will be no hypothesis testing in this study.
Detailed Description
As specified by Phase 1 protocol-flexible language in the protocol, modifications to the dose or dosing regimen can be made to achieve the scientific goals of the study objectives and/or to ensure appropriate safety of the study participants. The proposed doses for each Panel may be adjusted downward based on evaluation of observed safety, tolerability, and PK data.
Conditions Module
Conditions
Schizophrenia
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 1
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
75Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg
Experimental
Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
Drug: MK-8189
Panel A (Healthy Participants): Placebo Monotherapy
Placebo Comparator
Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
Drug: Placebo
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg
Experimental
Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
Drug: MK-8189
Panel B (Schizophrenia Participants): Placebo Monotherapy
Placebo Comparator
Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
Drug: Placebo
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg
Interventions
Name
Type
Description
Arm Group Labels
Other Names
MK-8189
Drug
MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
The Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, safety was analyzed by panel and dose. The number of participants who experienced one or more AEs was reported.
Up to ~32 days
The Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, safety was analyzed by panel and dose. The number of participants who discontinued study treatment due to an AE was reported.
Up to ~18 days
Secondary Outcomes
Measure
Description
Time Frame
Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC0-24hr) of MK-8189
AUC was a measure of MK-8189 exposure assessed as a product of drug concentration and time, using a linear mixed effects model. To estimate AUC0-24hr per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D). Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol AUC0-24hr was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of AUC0-24hr analysis and these arms were excluded. Geometric coefficient of variation (GCV) was reported as a percent. Per protocol placebo arms were excluded from AUC0-24hr analysis.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria
Panel A (Healthy Participants)
- If participant is of Japanese descent, both biological parents and all biological grandparents must be born in Japan.
Panels B and D (Participants with Schizophrenia; MK-8189 or Placebo Monotherapy / 15-Day Titration Monotherapy) - Is able to discontinue the use of all antipsychotic medication at least 5 days prior to the start of the treatment period and during the study period.
Panels B, C, and D (Participants with Schizophrenia; MK-8189 or Placebo Monotherapy / Add-on Therapy / 15-Day Titration Monotherapy)
Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria with the onset of the first episode being no less than 2 years prior to screening and monotherapy with antipsychotics for treatment should be indicated.
Is in the non-acute phase of their illness and clinically stable for 3 months prior to screening as demonstrated by: a.) no clinically significant change in dose of prescribed antipsychotic medication, or clinically significant change in antipsychotic medication to treat symptoms of schizophrenia for 2 months prior to screening; b.) no increase in level of psychiatric care due to worsening of symptoms of schizophrenia for 3 months prior to screening.
Has a history of receiving and tolerating antipsychotic medication within the usual dose range employed for schizophrenia.
Has a stable living situation in which the participant or a contact person can be reached by the investigator if there is a need for follow up.
Participants with hypothyroidism, diabetes, high blood pressure, chronic respiratory conditions or other mild forms of these medical conditions could be considered as candidates for study enrollment if their condition is stable and the prescribed dose and regimen of medication is stable for at least 3 months prior to screening and there are no expected changes in co-medication during the study.
Has regular bowel movements.
Panels A, B, C, and D
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
Is not a woman of childbearing potential (WOCBP)
Is a WOCBP and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 14 days after the last dose of study intervention.
Exclusion Criteria
Panel A (Healthy Participants)
Has a history of clinically diagnosed depression, anxiety disorder, or any history of psychiatric disorders having required drug treatment or hospitalization. Participants who have had situational depression more than 5 years before the start of the study may be enrolled in the study at the discretion of the investigator.
Has a history of stroke, chronic seizures, or major neurological disorder.
Has a history of dystonic reaction to antipsychotic, anti-emetic or related medication.
Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicide Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to item 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 5 years or suicidal behavior in their lifetime.
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events may be enrolled in the study at the discretion of the investigator.
Is mentally or legally incapacitated, has a history of clinically significant psychiatric disorder of the last 5 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies, beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit.
Is a smoker and/or has used nicotine or nicotine-containing products (e.g., nicotine patch and electronic cigarette) within 3 months of screening.
Panels B, C, and D (Participants with Schizophrenia; MK-8189 or Placebo Monotherapy / Add-on Therapy / 15-Day Titration Monotherapy)
Has evidence or history of a primary DSM-5 axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder per the allowed DSM-5 criteria within 1 month of screening.
Has evidence or history of mental retardation, borderline personality disorder, anxiety disorder, or organic brain syndrome.
Has a history of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia (TD).
Has a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
Has a DSM-5 defined substance abuse or dependence disorder (excluding nicotine and caffeine) within three months of screening.
Has a history of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures.
Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to item 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
Has received treatment with clozapine for schizophrenia or treatment with monoamine oxidase inhibitors within 3 months of screening. For Panel C participants, has received a total daily dose of risperidone > 6 mg.
Is unable to refrain from the use of co-medication with a moderate or strong inhibiting or inducing effect on cytochrome P450 (CYP) 3A (CYP3A) and/or CYP2C9 beginning approximately 2 weeks or 5 half- lives, whichever is longer, prior to administration of the initial dose of trial drug and throughout the trial or is unable to refrain from the use of sensitive substrates of CYP2B6. Unable to refrain from cyclic hormone replacement therapy. There may be certain medications that are permitted
Has received a parenteral depot antipsychotic medication within 3 months of pre-trial (screening).
Panels A, B, C, and D
Is a woman of childbearing potential (WOCBP) who has a positive serum pregnancy test at the screening visit or a positive urine pregnancy test within 48 hours before the first dose of study intervention. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Has a history of cancer (malignancy). Exceptions include: (1) Participants with adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the study; (2) Participants with other malignancies which have been successfully treated ≥10 years prior to the prestudy (screening) visit where, in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the prestudy (screening) visit (except those cancers identified at the beginning of this exclusion criteria); or (3) Participants, who, in the opinion of the study investigator, are highly unlikely to sustain a recurrence for the duration of the study.
Has a clinically significant history or presence of sick sinus syndrome, first, second, or third degree atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QTc interval, or conduction abnormalities.
Has history of repeated or frequent syncope, vasovagal episodes, or epileptic seizures.
Has a family history of sudden death.
Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or non-prescription drugs or food.
Has Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV) infection.
Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit. The window will be derived from the date of the last visit in the previous study.
Has history or presence of risk factors for Torsade de Pointes (e.g., cardiac disease, heart failure, hypokalaemia or hypomagnesaemia, hypertrophy, cardiomyopathy, or family history of long QT syndrome). Plasma calcium must be within normal limits at screening and serum calcium must be within normal limits prior to dosing.
Is under the age of legal consent.
Has been in incarceration or imprisonment within 3 months prior to screening.
Consumes greater than 3 glasses of alcoholic beverages per day. Participants who consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator.
Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 years.
Per protocol-specified dose modification, Panel C MK-8189 dose and schedule were modified, based on tolerability.
Recruitment Details
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg
Healthy participants received MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
FG001
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Not provided
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
0
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Not provided
Uploaded Document Information
Type
Includes Protocol
Includes SAP
Includes ICF
Document Label
Document Date
Document Uploaded Date
Document File Name
Prot_SAP
Yes
Yes
No
Study Protocol and Statistical Analysis Plan
Sep 9, 2019
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Double
Masking Description
Not provided
Who Masked
ParticipantInvestigator
Experimental
In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
Drug: MK-8189
Drug: Background AAP Therapy
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
Placebo Comparator
In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
Drug: Placebo
Drug: Background AAP Therapy
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg
Experimental
Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
Drug: MK-8189
Panel D (Schizophrenia Participants): Placebo Monotherapy
Placebo Comparator
Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
Drug: Placebo
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg
Placebo
Drug
MK-8189 dose-matching placebo tablets will be administered orally QD.
Panel A (Healthy Participants): Placebo Monotherapy
Panel B (Schizophrenia Participants): Placebo Monotherapy
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
Panel D (Schizophrenia Participants): Placebo Monotherapy
Background AAP Therapy
Drug
Participants with schizophrenia in Panel C will be on background therapy with an AAP medication (e.g., olanzapine, quetiapine, paliperidone, asenapine, iloperidone, aripirprazole, lurasidone, risperidone [not to exceed daily dose of 6 mg], or ziprasidone) throughout the study. Participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: clozapine is not allowed.
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D); Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D: Days 1, 4, 7, 10, 13, 15
Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189
Cmax was the maximum concentration of MK-8189 observed in plasma, assessed using a linear mixed effects model. To estimate Cmax, per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D); additional post-dose samples collected at 36, 48 hours on Days 18 and 15. Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol Cmax was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of Cmax analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from Cmax analysis.
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D);additional 36, 48 hours post-dose on Days 18, 15; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D:Days 1, 4, 7, 10, 13, 15
Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189
C24hr was the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189, assessed using a linear mixed effects model. To estimate C24hr, per protocol blood samples were collected 24 hours post-dose on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol C24hr was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of C24hr analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from C24hr analysis.
24 hours post-dose; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D: Days 1, 4, 7, 10, 13, 15
Time Post-dose to Maximum Observed Plasma Concentration (Tmax) of MK-8189
Tmax was the actual sampling time at which maximum post-dose plasma concentration of MK-8189 was observed. To estimate Tmax, per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D); additional post-dose samples collected at 36, 48 hours on Days 18 and 15. Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol Tmax was analyzed by panel, dose, dosing regimen; due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of Tmax analysis and were excluded. Per protocol placebo arms were excluded from Tmax analysis.
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D);additional 36, 48 hours post-dose on Days 18, 15; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D:Days 1, 4, 7, 10, 13, 15
Apparent Total Plasma Clearance of MK-8189 (CL/F) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
CL/F was the apparent total clearance of MK-8189 in plasma over time, assessed as the rate at which MK-8189 was removed from the plasma. To estimate CL/F, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol CL/F was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of CL/F analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from CL/F analysis.
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
Apparent Volume of MK-8189 Distribution (Vd/F) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
Vd/F was the apparent volume of distribution of MK-8189 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-8189 that would need to be uniformly distributed to achieve the desired plasma drug concentration. To estimate Vd/F, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol Vd/F was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of Vd/F analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from Vd/F analysis.
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent Terminal Half-life [t1/2]) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
t1/2 was the time required to divide the plasma concentration of MK-8189 by half after reaching pseudo-equilibrium. At least three quantifiable terminal phase concentrations collected were used to calculate t1/2. To estimate t1/2, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol t1/2 was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of t1/2 analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from t1/2 analysis.
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18.
FG002
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
FG003
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-18.
FG004
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg
In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
FG005
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-8 mg
In addition to background AAP treatment, participant with Schizophrenia received modified regimen of MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 8 mg, as follows: Days 1-3: 4 mg, Days 4-11: 8 mg.
FG006
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
FG007
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg.
FG008
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15.
FG00012 subjects
FG0014 subjects
FG00212 subjects
FG0034 subjects
FG00412 subjects
FG0051 subjects
FG0064 subjects
FG00717 subjects
FG0089 subjects
COMPLETED
FG00012 subjects
FG0014 subjects
FG00211 subjects
FG0034 subjects
FG0048 subjects
FG0050 subjects
FG0063 subjects
FG0079 subjects
FG0088 subjects
NOT COMPLETED
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG0044 subjects
FG0051 subjects
FG0061 subjects
FG0078 subjects
FG0081 subjects
Type
Comment
Reasons
Protocol Violation
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG0041 subjects
FG0050 subjects
FG0060 subjects
FG0071 subjects
FG0080 subjects
Sponsor decision
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG004
Physician Decision
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg
Healthy participants received MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
BG001
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18.
BG002
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
BG003
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-18.
BG004
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg
In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg.
BG005
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-8 mg
In addition to background AAP treatment, participant with Schizophrenia received modified regimen of MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 8 mg, as follows: Days 1-3: 4 mg, Days 4-11: 8 mg.
BG006
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
BG007
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg.
BG008
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15.
BG009
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00012
BG0014
BG00212
BG0034
BG00412
BG0051
BG0064
BG00717
BG0089
BG00975
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Standard Deviation
Years
Title
Denominators
Categories
Title
Measurements
BG00036.8± 8.2
BG00143.3± 15.4
BG00249.3± 9.5
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0008
BG0012
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0011
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Secondary
Area Under the Plasma-concentration Curve at Zero to 24 Hours Post-dose (AUC0-24hr) of MK-8189
AUC was a measure of MK-8189 exposure assessed as a product of drug concentration and time, using a linear mixed effects model. To estimate AUC0-24hr per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D). Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol AUC0-24hr was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of AUC0-24hr analysis and these arms were excluded. Geometric coefficient of variation (GCV) was reported as a percent. Per protocol placebo arms were excluded from AUC0-24hr analysis.
All participants who got ≥1 dose of MK-8189, had AUC0-24hr data for Days 7, 10, 13, 16 or 18 (Panels A, B); Days 9, 12, 15 or 18 (Panel C); Days 1, 4, 7, 10, 13 or 15 (Panel D). Per protocol AUC0-24hr was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints shown by 0 participants analyzed. The 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) arms weren't applicable to the AUC0-24hr timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
nM*hr
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D); Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D: Days 1, 4, 7, 10, 13, 15
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
Units
Counts
Participants
OG0000
OG0010
OG00211
OG003
Title
Denominators
Categories
Day 1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Primary
The Number of Participants Who Experienced One or More Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, safety was analyzed by panel and dose. The number of participants who experienced one or more AEs was reported.
All participants who got ≥1 dose of study drug. Per protocol, safety was analyzed by panel and dose.
Posted
Count of Participants
Participants
Up to ~32 days
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
Primary
The Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, safety was analyzed by panel and dose. The number of participants who discontinued study treatment due to an AE was reported.
All participants who got ≥1 dose of study drug. Per protocol, safety was analyzed by panel and dose.
Posted
Count of Participants
Participants
Up to ~18 days
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
Secondary
Maximum Observed Post-dose Plasma Concentration (Cmax) of MK-8189
Cmax was the maximum concentration of MK-8189 observed in plasma, assessed using a linear mixed effects model. To estimate Cmax, per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D); additional post-dose samples collected at 36, 48 hours on Days 18 and 15. Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol Cmax was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of Cmax analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from Cmax analysis.
All participants who got ≥1 dose of MK-8189, had Cmax data for Days 7, 10, 13, 16 or 18 (Panels A, B); Days 9, 12, 15 or 18 (Panel C); Days 1, 4, 7, 10, 13 or 15 (Panel D). Per protocol Cmax was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints shown by 0 participants analyzed. The 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) arms weren't applicable to the Cmax timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
nM
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D);additional 36, 48 hours post-dose on Days 18, 15; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D:Days 1, 4, 7, 10, 13, 15
ID
Title
Description
Secondary
Plasma Concentration at 24 Hours Post-dose (C24hr) of MK-8189
C24hr was the concentration of MK-8189 observed in plasma at the 24-hour nominal sampling time after administration of MK-8189, assessed using a linear mixed effects model. To estimate C24hr, per protocol blood samples were collected 24 hours post-dose on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol C24hr was analyzed by panel, dose, dosing regimen; due to differing dosing regimen some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of C24hr analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from C24hr analysis.
All participants who got ≥1 dose of MK-8189, had C24hr data for Days 7, 10, 13, 16 or 18 (Panels A, B); Days 9, 12, 15 or 18 (Panel C); Days 1, 4, 7, 10, 13 or 15 (Panel D). Per protocol C24hr was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints shown by 0 participants analyzed. The 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) arms weren't applicable to the C24hr timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
nM
24 hours post-dose; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D: Days 1, 4, 7, 10, 13, 15
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
Secondary
Time Post-dose to Maximum Observed Plasma Concentration (Tmax) of MK-8189
Tmax was the actual sampling time at which maximum post-dose plasma concentration of MK-8189 was observed. To estimate Tmax, per protocol blood samples were collected pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose for Panels A, B, C, D; no pre-dose samples collected on Day 18 (Panels A, B, C), Day 15 (Panel D); additional post-dose samples collected at 36, 48 hours on Days 18 and 15. Samples were collected on Days 7, 10, 13, 16, 18 for Panels A, B; Days 9, 12, 15, 18 for Panel C; Days 1, 4, 7, 10, 13, 15 for Panel D. Per protocol Tmax was analyzed by panel, dose, dosing regimen; due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) study arms weren't applicable to the protocol-specified timepoints/days of Tmax analysis and were excluded. Per protocol placebo arms were excluded from Tmax analysis.
All participants who got ≥1 dose of MK-8189, had Tmax data for Days 7, 10, 13, 16 or 18 (Panels A, B); Days 9, 12, 15 or 18 (Panel C); Days 1, 4, 7, 10, 13 or 15 (Panel D). Per protocol Tmax was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints shown by 0 participants analyzed. The 4 mg, 8 mg (Panels A, B), 4 mg (Panel C) arms weren't applicable to the Tmax timepoints; per protocol these arms and placebo arms were excluded.
Posted
Median
Full Range
hr
Pre-dose, 2, 6, 8, 10, 12, 16, 24 hours post-dose; no pre-dose on Day 18 (Panel A, B, C), Day 15 (Panel D);additional 36, 48 hours post-dose on Days 18, 15; Panel A, B: Days 7, 10, 13, 16, 18; Panel C: Days 9, 12, 15, 18; Panel D:Days 1, 4, 7, 10, 13, 15
ID
Title
Description
OG000
Secondary
Apparent Total Plasma Clearance of MK-8189 (CL/F) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
CL/F was the apparent total clearance of MK-8189 in plasma over time, assessed as the rate at which MK-8189 was removed from the plasma. To estimate CL/F, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol CL/F was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of CL/F analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from CL/F analysis.
All participants who got ≥1 dose of MK-8189, had CL/F data for Day 18 (Panels A, B, C) or Day 15 (Panel D). Per protocol CL/F was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints, shown by 0 participants analyzed. The 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) arms weren't applicable to the CL/F timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
Liter/hr
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
Secondary
Apparent Volume of MK-8189 Distribution (Vd/F) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
Vd/F was the apparent volume of distribution of MK-8189 between the plasma and the rest of the body, after dose, assessed as the total volume of MK-8189 that would need to be uniformly distributed to achieve the desired plasma drug concentration. To estimate Vd/F, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol Vd/F was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of Vd/F analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from Vd/F analysis.
All participants who got ≥1 dose of MK-8189, had Vd/F data for Day 18 (Panels A, B, C) or Day 15 (Panel D). Per protocol Vd/F was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints, shown by 0 participants analyzed. The 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) arms weren't applicable to the Vd/F timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
Liter
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Secondary
Time Required for Plasma Concentration of MK-8189 to Decrease by Half (Apparent Terminal Half-life [t1/2]) on Day 18 (Panels A, B, C) and Day 15 (Panel D)
t1/2 was the time required to divide the plasma concentration of MK-8189 by half after reaching pseudo-equilibrium. At least three quantifiable terminal phase concentrations collected were used to calculate t1/2. To estimate t1/2, per protocol blood samples were collected 2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 for Panels A, B, C, and on Day 15 for Panel D. Per protocol t1/2 was analyzed by panel, dose and dosing regimen. Due to differing dosing regimen, some arms/doses weren't applicable to some timepoints, shown by 0 participants analyzed in the table. Per dosing regimen, the 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) study arms weren't applicable to the protocol-specified timepoints/days of t1/2 analysis and were excluded. GCV was reported as a percent. Per protocol placebo arms were excluded from t1/2 analysis.
All participants who got ≥1 dose of MK-8189, had t1/2 data for Day 18 (Panels A, B, C) or Day 15 (Panel D). Per protocol t1/2 was analyzed by panel, dose, dosing regimen; based on dosing, some arms weren't applicable to some timepoints, shown by 0 participants analyzed. The 4 mg, 8 mg, 12 mg, 16 mg, 20 mg (Panels A, B, C), 8 mg, 16 mg, 24 mg, 36 mg (Panel D) arms weren't applicable to the t1/2 timepoints; per protocol these arms and placebo arms were excluded.
Posted
Geometric Mean
Geometric Coefficient of Variation
hr
2, 6, 8, 10, 12, 16, 24, 36, 48 hours post-dose on Day 18 (Panel A, B, C) and Day 15 (Panel D)
ID
Title
Description
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Time Frame
Serious AEs, Non-serious AEs: Up to ~32 Days, All-cause mortality: Up to ~21 months
Description
Safety was analyzed by panel and by dose, in all participants who received at least one dose of the study drug.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
0
12
0
12
5
12
EG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
0
12
0
12
3
12
EG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
0
11
0
11
4
11
EG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
0
11
0
11
5
11
EG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
0
10
0
10
2
10
EG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
0
10
0
10
5
10
EG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
0
4
0
4
3
4
EG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
0
12
0
12
4
12
EG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
0
11
0
11
3
11
EG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
0
11
0
11
4
11
EG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
0
11
0
11
8
11
EG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
0
10
0
10
5
10
EG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
0
10
0
10
7
10
EG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-18
0
4
0
4
4
4
EG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
0
13
0
13
6
13
EG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
0
11
0
11
8
11
EG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
0
10
0
10
5
10
EG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
0
8
0
8
5
8
EG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
0
7
0
7
4
7
EG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
0
7
0
7
4
7
EG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
0
4
0
4
1
4
EG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
0
17
0
17
8
17
EG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
0
16
0
16
8
16
EG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
0
15
0
15
5
15
EG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
0
13
1
13
4
13
EG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
0
11
0
11
8
11
EG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
0
9
0
9
9
9
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Psychotic disorder
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG0030 events0 affected11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Atrial fibrillation
Cardiac disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG0030 events0 affected11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
Palpitations
Cardiac disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Postural orthostatic tachycardia syndrome
Cardiac disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Asthenopia
Eye disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Eye irritation
Eye disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Abdominal discomfort
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Abdominal pain lower
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dyspepsia
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Gastrooesophageal reflux disease
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Gingival pain
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Glossodynia
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Paraesthesia oral
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Salivary hypersecretion
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Tongue dry
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Chest discomfort
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Chest pain
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Fatigue
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Feeling hot
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Feeling of body temperature change
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Non-cardiac chest pain
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Vessel puncture site pain
General disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Skin abrasion
Injury, poisoning and procedural complications
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Skin laceration
Injury, poisoning and procedural complications
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Blood pressure increased
Investigations
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Orthostatic heart rate response increased
Investigations
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Decreased appetite
Metabolism and nutrition disorders
MedDRA 23.0
Systematic Assessment
EG0002 events2 affected12 at risk
EG0011 events1 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0011 events1 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Flank pain
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Muscle tightness
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Muscle twitching
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Musculoskeletal pain
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Neck pain
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Akathisia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dizziness
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dyskinesia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dystonia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Extrapyramidal disorder
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Head discomfort
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Headache
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0022 events2 affected11 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Parosmia
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Somnolence
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0011 events1 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Syncope
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Tremor
Nervous system disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Dissociation
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Insomnia
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Nightmare
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Panic attack
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Paranoia
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Psychotic disorder
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Restlessness
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Tic
Psychiatric disorders
MedDRA 23.0
Systematic Assessment
EG0001 events1 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Breast tenderness
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dysmenorrhoea
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0021 events1 affected11 at risk
EG003
Vulvovaginal pruritus
Reproductive system and breast disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dyspnoea
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Hyperventilation
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Throat irritation
Respiratory, thoracic and mediastinal disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dermatitis
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dermatitis contact
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Dry skin
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0011 events1 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Skin lesion
Skin and subcutaneous tissue disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Hypertension
Vascular disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Orthostatic hypotension
Vascular disorders
MedDRA 23.0
Systematic Assessment
EG0000 events0 affected12 at risk
EG0010 events0 affected12 at risk
EG0020 events0 affected11 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
Point of Contact
Title
Organization
Phone
Extension
Email
Senior Vice President, Global Clinical Development
Schizophrenia Spectrum and Other Psychotic Disorders
D001523
Mental Disorders
Browse Leaves
Not provided
Browse Branches
Not provided
ID
Term
C000729358
MK-8189
Ancestor Terms
Not provided
Browse Leaves
Not provided
Browse Branches
Not provided
1 subjects
FG0051 subjects
FG0060 subjects
FG0070 subjects
FG0080 subjects
2 subjects
FG0050 subjects
FG0061 subjects
FG0075 subjects
FG0081 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0071 subjects
FG0080 subjects
0 subjects
FG0050 subjects
FG0060 subjects
FG0071 subjects
FG0080 subjects
44.0
± 8.9
BG00444.3± 7.1
BG00551.0± NAMeasure of dispersion could not be estimated due to low number of participants analyzed
BG00647.8± 7.2
BG00744.4± 10.0
BG00841.7± 9.6
BG00943.8± 9.6
6
BG0030
BG0045
BG0051
BG0062
BG0078
BG0084
BG00936
Male
BG0004
BG0012
BG0026
BG0034
BG0047
BG0050
BG0062
BG0079
BG0085
BG00939
1
BG0031
BG0041
BG0050
BG0060
BG0072
BG0080
BG0096
Not Hispanic or Latino
BG00012
BG0013
BG00211
BG0033
BG00411
BG0051
BG0064
BG00715
BG0089
BG00969
Unknown or Not Reported
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
0
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
Asian
BG0006
BG0012
BG0020
BG0031
BG0040
BG0050
BG0060
BG0070
BG0080
BG0099
Native Hawaiian or Other Pacific Islander
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
Black or African American
BG0003
BG0011
BG00211
BG0032
BG00410
BG0051
BG0064
BG00714
BG0088
BG00954
White
BG0003
BG0011
BG0021
BG0031
BG0040
BG0050
BG0060
BG0073
BG0081
BG00910
More than one race
BG0000
BG0010
BG0020
BG0030
BG0042
BG0050
BG0060
BG0070
BG0080
BG0092
Unknown or Not Reported
BG0000
BG0010
BG0020
BG0030
BG0040
BG0050
BG0060
BG0070
BG0080
BG0090
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participant with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
11
OG00410
OG00510
OG0060
OG0070
OG0080
OG00911
OG01011
OG01110
OG01210
OG0130
OG0140
OG0151
OG01610
OG0178
OG0187
OG0197
OG0200
OG02117
OG02216
OG02315
OG02413
OG02511
OG0260
0
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG02117
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG0214640± 40.5
Day 4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG02216
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG02210900± 72.1
Day 7
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG00211
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG00911
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG02315
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG0028360± 42.5
OG00911700± 32.9
OG02314100± 106.6
Day 9
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0151
ParticipantsOG01610
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG01511400± NAMeasure of dispersion could not be estimated due to low number of participants analyzed
OG01611300± 47.9
Day 10
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG00311
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG01011
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG02413
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG00310200± 49.0
OG01017200± 41.9
OG02425100± 54.6
Day 12
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0178
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG01713800± 28.2
Day 13
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG00410
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG00412200± 48.5
OG01120200± 44.7
OG02531800± 54.5
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0187
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG01815700± 33.4
OG02534400± 66.5
Day 16
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG00515600± 36.1
OG01224600± 36.6
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0197
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG00513600± 59.6
OG01226600± 38.3
OG01918900± 30.8
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG00012
OG00112
OG00211
OG00311
OG00410
OG00510
OG0064
OG00712
OG00811
OG00911
OG01011
OG01110
OG01210
OG0134
OG01413
OG01511
OG01610
OG0178
OG0187
OG0197
OG0204
OG02117
OG02216
OG02315
OG02413
OG02511
OG0269
Title
Denominators
Categories
Title
Measurements
OG0005
OG0013
OG0024
OG0035
OG0042
OG0055
OG0063
OG0074
OG0083
OG0094
OG0108
OG0115
OG0127
OG0134
OG0146
OG0158
OG0165
OG0175
OG0184
OG0194
OG0201
OG0218
OG0228
OG0235
OG0245
OG0258
OG0269
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG00012
OG00112
OG00211
OG00311
OG00410
OG00510
OG0064
OG00712
OG00811
OG00911
OG01011
OG01110
OG01210
OG0134
OG01413
OG01511
OG01610
OG0178
OG0187
OG0197
OG0204
OG02117
OG02216
OG02315
OG02413
OG02511
OG0269
Title
Denominators
Categories
Title
Measurements
OG0001
OG0010
OG0020
OG0031
OG0040
OG0050
OG0060
OG0071
OG0080
OG0090
OG0101
OG0110
OG0120
OG0131
OG0141
OG0151
OG0163
OG0171
OG0180
OG0190
OG0200
OG0211
OG0223
OG0230
OG0241
OG0250
OG0262
OG000
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participant with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG00211
OG00311
OG00410
OG00510
OG0060
OG0070
OG0080
OG00911
OG01011
OG01110
OG01210
OG0130
OG0140
OG0151
OG01610
OG0178
OG0187
OG0197
OG0200
OG02117
OG02216
OG02315
OG02413
OG02511
OG0260
Title
Denominators
Categories
Day 1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG02117
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG021328± 42.8
Day 4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 7
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG00211
ParticipantsOG0030
Day 9
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 10
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG00311
Day 12
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 13
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 16
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participant with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG00211
OG0036
OG00410
OG00510
OG0060
OG0070
OG0080
OG00911
OG01011
OG01110
OG01210
OG0130
OG0140
OG0151
OG01610
OG0178
OG0186
OG0197
OG0200
OG02117
OG02216
OG02314
OG02413
OG02511
OG0260
Title
Denominators
Categories
Day 1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG02117
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG021287± 70.3
Day 4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 7
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG00211
ParticipantsOG0030
Day 9
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 10
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0036
Day 12
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 13
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 16
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Panel A (Healthy Participants): MK-8189 Monotherapy 4 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participant with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG00211
OG00311
OG00410
OG00510
OG0060
OG0070
OG0080
OG00911
OG01011
OG01110
OG01210
OG0130
OG0140
OG0151
OG01610
OG0178
OG0187
OG0197
OG0200
OG02117
OG02216
OG02315
OG02413
OG02511
OG0260
Title
Denominators
Categories
Day 1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG02117
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG02123.95(12.00 to 24.00)
Day 4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 7
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG00211
ParticipantsOG0030
Day 9
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 10
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG00311
Day 12
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 13
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 16
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0030
OG0040
OG00510
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
OG01210
OG0130
OG0140
OG0150
OG0160
OG0170
OG0180
OG0197
OG0200
OG0210
OG0220
OG0230
OG0240
OG02511
OG0260
Title
Denominators
Categories
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG0253.65± 66.5
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0030
OG0040
OG00510
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
OG01210
OG0130
OG0140
OG0150
OG0160
OG0170
OG0180
OG0197
OG0200
OG0210
OG0220
OG0230
OG0240
OG02510
OG0260
Title
Denominators
Categories
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02510
ParticipantsOG0260
Title
Measurements
OG02547.1± 48.0
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Healthy participants received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG001
Panel A (Healthy Participants): MK-8189 Monotherapy 8 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG002
Panel A (Healthy Participants): MK-8189 Monotherapy 12 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG003
Panel A (Healthy Participants): MK-8189 Monotherapy 16 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG004
Panel A (Healthy Participants): MK-8189 Monotherapy 20 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG005
Panel A (Healthy Participants): MK-8189 Monotherapy 24 mg
Healthy participants received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG006
Panel A (Healthy Participants): Placebo Monotherapy
Healthy participants received MK-8189 monotherapy matching placebo orally QD on Days 1-18
OG007
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG008
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG009
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 12 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG010
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG011
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 20 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG012
Panel B (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG013
Panel B (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD from Days 1-18.
OG014
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 4 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG015
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 8 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 8 mg starting on Day 4 and continuing up to Day 11, based on participant tolerability
OG016
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 12 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 12 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG017
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 16 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 16 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG018
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 20 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 20 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG019
Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 24 mg
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy orally QD at a dose of 24 mg starting on Day 16 and continuing up to Day 18, based on participant tolerability
OG020
Panel C (Schizophrenia Participants): Placebo Add-on Therapy
In addition to background AAP treatment, participants with Schizophrenia received MK-8189 add-on therapy matching placebo orally QD on Days 1-18
OG021
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 8 mg starting on Day 1 and continuing up to Day 3, based on participant tolerability
OG022
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 16 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 16 mg starting on Day 4 and continuing up to Day 6, based on participant tolerability
OG023
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 24 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 24 mg starting on Day 7 and continuing up to Day 9, based on participant tolerability
OG024
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 36 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 36 mg starting on Day 10 and continuing up to Day 12, based on participant tolerability
OG025
Panel D (Schizophrenia Participants): MK-8189 Monotherapy 48 mg
Participants with Schizophrenia received MK-8189 monotherapy orally QD at a dose of 48 mg starting on Day 13 and continuing up to Day 15, based on participant tolerability
OG026
Panel D (Schizophrenia Participants): Placebo Monotherapy
Participants with Schizophrenia received MK-8189 monotherapy matching placebo orally QD on Days 1-15
Units
Counts
Participants
OG0000
OG0010
OG0020
OG0030
OG0040
OG00510
OG0060
OG0070
OG0080
OG0090
OG0100
OG0110
OG01210
OG0130
OG0140
OG0150
OG0160
OG0170
OG0180
OG0197
OG0200
OG0210
OG0220
OG0230
OG0240
OG02510
OG0260
Title
Denominators
Categories
Day 15
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
ParticipantsOG0040
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02510
ParticipantsOG0260
Title
Measurements
OG0258.25± 20.0
Day 18
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
1 events
1 affected
11 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
1 events
1 affected
11 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0262 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0103 events3 affected11 at risk
EG0112 events2 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0171 events1 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0091 events1 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0231 events1 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0071 events1 affected12 at risk
EG0081 events1 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0111 events1 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0101 events1 affected11 at risk
EG0111 events1 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0181 events1 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0211 events1 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0252 events2 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0231 events1 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0101 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0181 events1 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0111 events1 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0041 events1 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0132 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0211 events1 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0111 events1 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0111 events1 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0142 events2 affected13 at risk
EG0152 events2 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0181 events1 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0211 events1 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0202 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0232 events2 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0262 events2 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0101 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0071 events1 affected12 at risk
EG0080 events0 affected11 at risk
EG0092 events2 affected11 at risk
EG0100 events0 affected11 at risk
EG0111 events1 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0101 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0211 events1 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
1 events
1 affected
11 at risk
EG0040 events0 affected10 at risk
EG0052 events2 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0101 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0152 events2 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0253 events3 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0081 events1 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
4 events
4 affected
11 at risk
EG0040 events0 affected10 at risk
EG0053 events3 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0082 events2 affected11 at risk
EG0092 events2 affected11 at risk
EG0102 events2 affected11 at risk
EG0111 events1 affected10 at risk
EG0124 events3 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0152 events2 affected11 at risk
EG0160 events0 affected10 at risk
EG0172 events2 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0211 events1 affected17 at risk
EG0223 events3 affected16 at risk
EG0232 events2 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0262 events2 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0181 events1 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0214 events4 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0121 events1 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0091 events1 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0181 events1 affected7 at risk
EG0191 events1 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0072 events1 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0123 events3 affected10 at risk
EG0130 events0 affected4 at risk
EG0141 events1 affected13 at risk
EG0150 events0 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0224 events4 affected16 at risk
EG0232 events2 affected15 at risk
EG0240 events0 affected13 at risk
EG0252 events2 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0102 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0052 events2 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0102 events2 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0211 events1 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0231 events1 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0102 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0171 events1 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0231 events1 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0102 events1 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
1 events
1 affected
11 at risk
EG0040 events0 affected10 at risk
EG0051 events1 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0171 events1 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0161 events1 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0071 events1 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0251 events1 affected11 at risk
EG0262 events2 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
1 events
1 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
1 events
1 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0151 events1 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0131 events1 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0212 events2 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0263 events3 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0061 events1 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0201 events1 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0241 events1 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0261 events1 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0170 events0 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0221 events1 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0171 events1 affected8 at risk
EG0180 events0 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
0 events
0 affected
11 at risk
EG0040 events0 affected10 at risk
EG0050 events0 affected10 at risk
EG0060 events0 affected4 at risk
EG0070 events0 affected12 at risk
EG0080 events0 affected11 at risk
EG0090 events0 affected11 at risk
EG0100 events0 affected11 at risk
EG0110 events0 affected10 at risk
EG0120 events0 affected10 at risk
EG0130 events0 affected4 at risk
EG0140 events0 affected13 at risk
EG0150 events0 affected11 at risk
EG0160 events0 affected10 at risk
EG0171 events1 affected8 at risk
EG0181 events1 affected7 at risk
EG0190 events0 affected7 at risk
EG0200 events0 affected4 at risk
EG0210 events0 affected17 at risk
EG0220 events0 affected16 at risk
EG0230 events0 affected15 at risk
EG0240 events0 affected13 at risk
EG0250 events0 affected11 at risk
EG0260 events0 affected9 at risk
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG02216
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG022619± 52.5
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG00911
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG02315
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG002481± 41.6
OG009588± 33.7
OG023920± 54.5
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0151
ParticipantsOG01610
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG015591± NAMeasure of dispersion could not be estimated due to low number of participants analyzed
OG016566± 46.3
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG01011
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG02413
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG003613± 37.2
OG010868± 41.5
OG0241390± 46.1
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0178
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG017693± 24.6
Participants
OG004
10
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG004709± 47.1
OG0111010± 45.0
OG0251670± 51.9
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0187
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG018801± 27.3
OG0251890± 52.9
Participants
OG004
0
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG005807± 34.0
OG0121250± 37.7
Participants
OG004
0
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0197
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG005741± 48.0
OG0121300± 36.8
OG019972± 23.4
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG02216
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG022480± 101.8
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG00911
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG02314
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG002310± 47.2
OG009501± 37.9
OG023567± 131.4
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0151
ParticipantsOG01610
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG015416± NAMeasure of dispersion could not be estimated due to low number of participants analyzed
OG016490± 54.0
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG01011
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG02413
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG003392± 61.4
OG010702± 46.9
OG024890± 80.3
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0178
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG017540± 39.1
Participants
OG004
10
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG01110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG004418± 65.0
OG011836± 57.0
OG0251370± 47.5
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0186
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG02511
ParticipantsOG0260
Title
Measurements
OG018651± 44.1
OG0251160± 97.8
Participants
OG004
0
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG005625± 39.7
OG012949± 45.7
Participants
OG004
0
ParticipantsOG00510
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG01210
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0197
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG005433± 111.3
OG0121010± 47.5
OG019704± 39.0
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG02216
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG02212.04(0.00 to 23.98)
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG00911
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0150
ParticipantsOG0160
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG02315
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG00212.02(8.00 to 16.02)
OG00915.98(6.00 to 23.95)
OG02316.03(0.00 to 23.97)
Participants
OG004
0
ParticipantsOG0050
ParticipantsOG0060
ParticipantsOG0070
ParticipantsOG0080
ParticipantsOG0090
ParticipantsOG0100
ParticipantsOG0110
ParticipantsOG0120
ParticipantsOG0130
ParticipantsOG0140
ParticipantsOG0151
ParticipantsOG01610
ParticipantsOG0170
ParticipantsOG0180
ParticipantsOG0190
ParticipantsOG0200
ParticipantsOG0210
ParticipantsOG0220
ParticipantsOG0230
ParticipantsOG0240
ParticipantsOG0250
ParticipantsOG0260
Title
Measurements
OG01512.00(NA to NA)Measure of dispersion could not be estimated due to low number of participants analyzed